紫杉醇脂质体联合顺铂治疗晚期食管癌的临床疗效研究

目的探讨紫杉醇脂质体联合顺铂治疗晚期食管癌的临床疗效及安全性。方法对38例患者随机分为试验组和对照组,试验组19例:紫杉醇脂质体135 mg/m2静脉滴注,第1天;顺铂25 mg/m2静脉滴注,第1~3天;对照组19例:氟尿嘧啶0.75/m2静脉滴注,第1~5天;顺铂25 mg/m2静脉滴注,第1~3天。21 d为1周期。结果试验组与对照组有效率分别为49.65%和26.31%,2组比较有统计学意义(P<0.05)。试验组及对照组中位疾病进展时间(mTTP)分别为4.6个月和3.7个月,中位生存期(mOS)分别为10.3个月和9.2个月,2组比较无统计学意义(P>0.05)。2组在血液学毒性、消化道反应、周围神经毒性及脱发方面比较无统计学意义(P>0.05)。结论紫杉醇脂质体联合顺铂方案治疗晚期食管癌具有较好的疗效和安全性。

Clinical observation of paclitaxel liposome combined with cisplatin in the treatment of patients with advanced esophaeal cancer

Objective To study the effects and adverse reactions of paclitaxel liposome combined with cisplatin in the treatment of patients with advanced esophageal cancer.Methods Thirty-eight patients were randomly divided into two groups.The experiment group received paclitaxel liposome at 135 mg/m2(IV drop d1) combined with cisplatin at 25 mg/m2(Iv drop d1-d3).The control group received paclitaxel at 80 mg/m2(IV drop d1-d5) combined with cisplatin at 25 mg/m2(IV drop d1-d3).The patients were repeatedly treated every 21 days.Results The total effectiveness rates of the experiment group and the control group were 49.65% and 26.31%,respectively(P<0.05).There was no significant difference between two groups in mTTP and mOS(P>0.05).The incidence rate of hematologic toxicity,gastrointestinal reactions,peripheral nerve toxicity and alopecia were similar in both groups(P>0.05).Conclusion Paclitaxel liposome combined with cisplatin has better efficacy and less adverse reactions in treating advanced esophageal cancer